Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naïve proliferative and severe nonproliferative diabetic retinopathy

Acta Ophthalmol. 2012 Nov;90(7):e573-4. doi: 10.1111/j.1755-3768.2011.02364.x. Epub 2012 Mar 9.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Bevacizumab
  • Diabetes Mellitus, Type 2 / complications
  • Diabetic Retinopathy / drug therapy
  • Diabetic Retinopathy / physiopathology
  • Diabetic Retinopathy / surgery
  • Diabetic Retinopathy / therapy*
  • Female
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Laser Coagulation*
  • Male
  • Middle Aged
  • Prospective Studies
  • Retinal Neovascularization / drug therapy
  • Retinal Neovascularization / physiopathology
  • Retinal Neovascularization / surgery
  • Retinal Neovascularization / therapy*
  • Retreatment
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity / physiology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab